MB, Levis & Associates’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

MB, Levis & Associates’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$677	Hold	21	–	–	﹤0.01%	245
2026 Q1	$622	Hold	21	–	–	﹤0.01%	224
2025 Q4	$604	Hold	21	–	–	﹤0.01%	236
2025 Q3	$349	Hold	21	–	–	﹤0.01%	239
2025 Q2	$1.72K	Hold	21	–	–	﹤0.01%	246
2025 Q1	$1.65K	Hold	21	–	–	﹤0.01%	253
2024 Q4	$3.49K	Hold	21	–	–	﹤0.01%	234
2024 Q3	$1.96K	Hold	21	–	–	﹤0.01%	259
2024 Q2	$2.05K	Hold	21	–	–	﹤0.01%	257
2024 Q1	$3.2K	Hold	21	–	–	﹤0.01%	238
2023 Q4	$2.43K	Hold	21	–	–	﹤0.01%	243
2023 Q3	$4.21K	Hold	21	–	–	﹤0.01%	225
2023 Q2	$4.27K	Hold	21	–	–	﹤0.01%	223
2023 Q1	$3.21K	Hold	21	–	–	﹤0.01%	236
2022 Q4	$2.81K	Buy	+21	New	+$4.2K	﹤0.01%	224

Other funds holding YARW

T3 Companies New York $93.7M AUM

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

FWA

Flagship Wealth Advisors Wakefield, Massachusetts $447M AUM 25.09% 1-Year Est. Return

MB, Levis & Associates's YARW Position: Q2 2026 in Review

MB, Levis & Associates held its Yarrow Bioscience, Inc. Common Stock (YARW) position steady in Q2 2026 at 21 shares worth $677. The position accounts for ﹤0.01% of the portfolio, ranked #245.

MB, Levis & Associates first reported a position in YARW in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.27K in Q2 2023. 4 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

MB, Levis & Associates held 21 shares of Yarrow Bioscience, Inc. Common Stock worth $677 as of Q2 2026.
MB, Levis & Associates left its Yarrow Bioscience, Inc. Common Stock share count unchanged in Q2 2026.
Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of MB, Levis & Associates's portfolio in Q2 2026, its #245 holding.
MB, Levis & Associates first reported a position in Yarrow Bioscience, Inc. Common Stock in Q4 2022 and has held it in 15 quarters since.
MB, Levis & Associates's Yarrow Bioscience, Inc. Common Stock position peaked at $4.27K in Q2 2023.
4 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.